Extensive 177Lu-PSMA radioligand therapy can lead to radiation nephropathy with a renal thrombotic microangiopathy–like picture
…, S Mayr, M Büttner-Herold, K Knorr, L Steinhelfer… - European Urology, 2023 - Elsevier
Lutetium-177 prostate-specific membrane antigen ( 177 Lu-PSMA) radioligand therapy is
an option that is increasingly being used for treatment of metastatic castration-resistant …
an option that is increasingly being used for treatment of metastatic castration-resistant …
Delayed imaging improves lesion detectability in [99mTc] Tc-PSMA-I&S SPECT/CT in recurrent prostate cancer
C Berliner, L Steinhelfer, M Chantadisai… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Our objective was to compare the ability to detect histopathologically confirmed lymph node
metastases by early and delayed [ 99m Tc]Tc-PSMA-I&S SPECT/CT in early biochemically …
metastases by early and delayed [ 99m Tc]Tc-PSMA-I&S SPECT/CT in early biochemically …
Pretherapeutic comparative dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer
…, R Tauber, J Allmann, L Steinhelfer… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands allow for labeling with
18 F and radiometals for endoradiotherapy. rhPSMA-7.3 has been designated as a lead …
18 F and radiometals for endoradiotherapy. rhPSMA-7.3 has been designated as a lead …
[HTML][HTML] Systemic therapy of necrobiotic xanthogranuloma: a systematic review
L Steinhelfer, T Kühnel, H Jägle, S Mayer… - Orphanet Journal of …, 2022 - Springer
Background Even though a plethora of systemic therapies have been proposed for necrobiotic
xanthogranuloma (NXG), there is no systematic review on this topic in literature. Objective …
xanthogranuloma (NXG), there is no systematic review on this topic in literature. Objective …
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
L Steinhelfer, L Lunger, L Cala, CH Pfob… - Journal of Nuclear …, 2024 - Soc Nuclear Med
β-emitting 177 Lu targeting prostate-specific membrane antigen (PSMA) is an approved
treatment option for metastatic castration-resistant prostate cancer. Data on its long-term …
treatment option for metastatic castration-resistant prostate cancer. Data on its long-term …
Prostate-specific membrane antigen–radioguided surgery facilitates pelvic lymph node dissection during radical prostatectomy for the treatment of locally advanced …
L Lunger, L Steinhelfer, P Korn, M Eiber… - European Urology …, 2023 - Elsevier
Lymph node metastases (LNMs) are common in intermediate- to high-risk prostate cancer (PC)
and may be missed during extended pelvic lymph node dissection (ePLND). Here we …
and may be missed during extended pelvic lymph node dissection (ePLND). Here we …
[HTML][HTML] Artificial intelligence support in MR imaging of incidental renal masses: an early health technology assessment
AW Marka, J Luitjens, FT Gassert, L Steinhelfer… - European …, 2024 - Springer
Objective This study analyzes the potential cost-effectiveness of integrating an artificial
intelligence (AI)–assisted system into the differentiation of incidental renal lesions as benign or …
intelligence (AI)–assisted system into the differentiation of incidental renal lesions as benign or …
Accelerated liver water T1 mapping using single‐shot continuous inversion‐recovery spiral imaging
Purpose Liver T 1 mapping techniques typically require long breath holds or long scan time
in free‐breathing, need correction for B 1 + $$ {\mathrm{B}}_1^{+} $$ inhomogeneities and …
in free‐breathing, need correction for B 1 + $$ {\mathrm{B}}_1^{+} $$ inhomogeneities and …
Pneumonitis after normofractionatedi Radoimmunotherapy: A method for Dose-Volume-Effect Correlation Evaluation
KM Kraus, C Bauer, L Steinhelfer, B Feuerecker… - 2024 - researchsquare.com
Background Post-Therapy-Pneumonitis (PTP) is a critical side effect of both, thoracic radio (chemo)
therapy (R (C) T) and immune checkpoint inhibition (ICI). However, disease …
therapy (R (C) T) and immune checkpoint inhibition (ICI). However, disease …
Platinum-based chemotherapy in patients with castration-resistant prostate cancer and hepatic metastases.
…, T Busenbender, M Kaune, P Tennstedt, L Steinhelfer… - 2023 - ascopubs.org
e17063 Background: Patients with metastatic castration-resistant prostate cancer (mCRPC)
and hepatic metastases face a dismal prognosis. In fact, the majority of phase 3 trials show …
and hepatic metastases face a dismal prognosis. In fact, the majority of phase 3 trials show …